Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.
Applied Biosystems TAP

Site Tools

  • AAAS
  • Subscribe
  • Feedback

Site Search

Search Advanced

Science 16 February 2001:
Vol. 291. no. 5507, pp. 1193 - 1203
DOI: 10.1126/science.291.5507.1193
Prev | Table of Contents | Next

News Focus

Genomania Meets the Bottom Line

David Malakoff and Robert F. Service

Many financial analysts remain wary of the growing genomics industry. Although a record number of self-proclaimed genomics firms went public last year, and a few established firms saw their stock prices temporarily skyrocket in anticipation of the completion of the human genome, longtime observers note that most genomics companies have yet to turn a profit. Even some high-profile players, such as information broker Celera Genomics of Rockville, Maryland, are still struggling to figure out how they will ultimately make money (see sidebar).

Read the Full Text

ADVERTISEMENT
Click Me!

ADVERTISEMENT
Click Me!

To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)